Colon Cancer Drugs Market Research Reports

Colon (or colorectal/bowel cancer) is diagnosed in over 1 million people annually, and accounts for over 0.5 million deaths each year. According to a recent article in the renowned Lancet medical journal, in Europe the 5-year survival for colorectal cancer is less than 60% so there is certainly considerable market potential for effective and accessible new pharmaceutical drugs. Reports in the Colon Cancer Section will help industry operators, and those considering entering this market, to answer the key questions such as what are the latest clinical trials, what are the R&D trends, what is the potential for personalized medicine, where are the opportunities in major markets such as China and the US, etc. Show Less Read more